EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies

Alexander P Landry, Justin Z Wang, Leeor S Yefet, Jeff Liu, Vikas Patil, Wen-Jiang Zhang, Julio Sosa, Yosef Ellenbogen, Chloe Gui, Andrew Ajisebutu, Kenneth Aldape iD, Andrew Gao und 4 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Alexander P Landry und 15 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Metabolome, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Our group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumors), has not been explored.

Methods

We performed untargeted metabolic profiling of meningiomas representing each molecular group and World Health Organization (WHO) grade. Prognostic biochemicals were identified using Cox regression and their biological importance was explored using RNA and protein-based pathway analyses. Validation was performed using targeted high performance liquid chromatography-mass spectrometry (HPLC-MS/MS).

Results

Global metabolic profiling identified 560 unique biochemicals. We identified a 21-metabolite outcome signature which is strongly predictive of outcome after adjusting for WHO grade, extent of resection, and receipt of adjuvant radiotherapy (HR = 326.49, 95% CI = 16.72-6375.48, P < .0001). The abundance of N6-trimethyllysine was associated with earlier time to recurrence on our whole cohort (log-rank P = .009) and within hypermetabolic and WHO grade 2 tumors specifically; this was validated using targeted HPLC-MS/MS on two cohorts. Consensus RNA and protein expression analysis demonstrated as association between N6-trimethyllysine abundance and activation of oxidative phosphorylation pathways, which portended worse outcomes in the hypermetabolic subgroup but, interestingly, better outcomes in the proliferative subgroup. By contrast, upregulated pyruvate and lactate transporters were associated with worse outcomes in proliferative meningiomas specifically.

Conclusions

This is the first study to demonstrate a subgroup-specific prognostic role of N6-trimethyllysine in hypermetabolic meningiomas, offering increasingly granular outcome predictions using a widely accessible technique (HPLC-MS/MS). We also suggest fundamental differences in preferred energy utilization between and a potential need for subgroup-specific therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsMetabolomeBiomarkers, TumorMetabolomicsHumansFemalePrognosisMaleMiddle AgedAgedTandem Mass SpectrometryAdultChromatography, High Pressure LiquidSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

RNA sequencingmeningiomametabolismmolecular classificationoutcome predictionproteomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Division of Laboratory Medicine and Pathobiology, University Health Network, Toronto, ON, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, Canada.

ORCID-Profile: Kenneth Aldape, Eric X Chen, Gelareh Zadeh

Förderung

  • NCI NIH HHS
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Landry, A. P., Wang, J. Z., Yefet, L. S., Liu, J., Patil, V., Zhang, W. J., Sosa, J., Ellenbogen, Y., Gui, C., Ajisebutu, A., Aldape, K., Gao, A., Kislinger, T., Chen, E. X., Nassiri, F., & Zadeh, G. (2025). Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae281

Vancouver

Landry AP, Wang JZ, Yefet LS, Liu J, Patil V, Zhang WJ, et al. Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae281

BibTeX
@article{Landry2025,
  author = {Landry, Alexander P and Wang, Justin Z and Yefet, Leeor S and Liu, Jeff and Patil, Vikas and Zhang, Wen-Jiang and Sosa, Julio and Ellenbogen, Yosef and Gui, Chloe and Ajisebutu, Andrew and Aldape, Kenneth and Gao, Andrew and Kislinger, Thomas and Chen, Eric X and Nassiri, Farshad and Zadeh, Gelareh},
  title = {Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae281}
}
Kostenlos starten →